Company Biography
Real-World Outcomes among Patients with Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors versus Immunotherapy with or without Chemotherapy in First-line Setting
Link to Abstract. A PDF of the poster is available to download under the Resources tab
Contact Information
Name
Jon Apple
Email
jon.apple@astrazeneca.com
You have chosen to your
information with
Real-World Outcomes among Patients with Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors versus Immunotherapy with or without Chemotherapy in First-line Setting
Team Members
Jon Apple, PharmD
Rahul Shenolikar, PhD
Kevin De Silva, MS
Ping Sun, PhD